ABOS
Acumen Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$199.31M
P/E Ratio
—
EPS
$-2.00
Beta
0.34
52W High
$3.60
52W Low
$0.85
50-Day MA
$2.75
200-Day MA
$1.94
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies for the treatment of Alzheimer's disease and other neurodegenerative diseases. The company is headquartered in Charlottesville, Virginia.
Fundamentals
| Revenue (TTM) | 329,000 |
| Gross Profit (TTM) | $-104.89M |
| EBITDA | $-123.77M |
| Operating Margin | 0.00% |
| Return on Equity | -96.20% |
| Return on Assets | -42.80% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $1.16 |
| Price-to-Book | 2.77 |
| Price-to-Sales (TTM) | 538.78 |
| EV/Revenue | 24.48 |
| EV/EBITDA | -0.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $72.21M |
| Float | $44.33M |
| % Insiders | 6.26% |
| % Institutions | 62.67% |
Analyst Ratings
Consensus ($7.40 target)
6
BuyData last updated: 4/7/2026